Regimen significantly improved survival over standard neoadjuvant chemotherapy ...

Gene expression signatures (GES) derived from digital histology to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (CT) in ISPY2 and other trial/real world cohorts. This is an ...

In Perioperative Immunotherapy Advances: Insights from CheckMate-77T and KEYNOTE-671, our panel delves into the following ...

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant chemotherapy significantly lowered 90-day postoperative mortality for advanced ovarian cancer across ...

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease ...

Please provide your email address to receive an email when new articles are posted on . Patients with pathologic complete response after neoadjuvant systemic therapy remained disease-free at 5 years ...

Long-term data from a prospective phase 2 trial show neoadjuvant cisplatin-based chemotherapy before nephroureterectomy provides durable survival benefits in high-risk, nonmetastatic UTUC. Neoadjuvant ...

Neoadjuvant immunotherapy plus chemotherapy shows a 35% pathological complete response rate and 49% major pathological response rate in LS-SCLC. Most patients achieved R0 surgical resection, with a 44 ...

Neoadjuvant chemotherapy with a regimen of gemcitabine-cisplatin for high-risk upper tract urothelial carcinoma (UTUC) resulted in a high rate of downstaging, and should now be considered a new ...